Method for treating blood coagulation disorders
View Patent ↗Provided is a method for treatment of blood coagulation disorders. The method comprises administering to an individual compositions comprising lipidic particles comprising phosphatidylcholine, phosphatidylinositol and cholesterol. One or more peptides, polypeptides or proteins involved in the blood coagulation cascade are associated with the lipidic particles.
1. A method of treating a blood coagulation disorder comprising administering to an individual a composition comprising lipidic particles and one or more therapeutic agents associated with the particles, wherein the lipidic particles comprise phosphatidylcholine (PC), phosphatidylinositol (PI) and cholesterol, wherein the ratio of PC to PI is between 60:40 to 40:60 and cholesterol is present between 5-15% of PC and PI together and the particles have a size of between 40 to 140 nm.
2. The method of claim 1 , wherein the PC to PI ratio is between 55:45 and 45:55.
3. The method of claim 2 , wherein the PC to PI ratio is 50:50.
4. The method of claim 1 , wherein each acyl chains of PC and PI independently has between 12 and 22 carbon atoms, and is saturated or unsaturated.
5. The method of claim 1 , wherein the PI is soy PI and the PC is egg PC.
6. The method of claim 1 , wherein the therapeutic agent is selected from the group consisting of Factor VIII, Factor VII, Factor IX, Factor V, Willebrand Factor (vWF) and von Heldebrant Factor (vHF).
7. The method of claim 6 , wherein the therapeutic agent in FVIII or B-domain deleted FVIII.
8. The method of claim 6 , wherein the therapeutic agent is FVII.
9. The method of claim 1 , wherein at least 50% of the lipidic particles have a size less than 140 nm.
10. The method of claim 9 , wherein at least 60%, 70% 80% or 90% of the lipidic particles have a size less than 140 nm.
11. The method of claim 10 , wherein at least 50%, 60%, 70%, 80% or 90% of the lipidic particles have a size between 40 to 100 nm.
12. The composition of claim 11 , wherein the size of the lipidic particles is between 80 and 100 nm.
13. The method of claim 1 , wherein the blood disorder is hemophilia.
14. The method of claim 1 , wherein the compositions is administered via intravenous, intraperitoneal, mucosal, oral, subcutaneous, transdermal or intradermal route.
15. The method of claim 1 , wherein the individual has developed antibodies to one or more proteins in the blood clotting cascade.
16. The method of claim 1 , wherein the individual has developed antibodies to Factor VIII.